Post Reply
81-100 of 1176
With the insurance unit also recovering and also two new experiences director joining 😁
Veteran bankers Eric Tham and Tan Jeh Wuan to join board of Raffles Medical?s insurance unit.
What are the prices waiting $1 dollars 🤔
Today RMG buying back 500 lots at 0.975, very impressive 🙏
Forget China.
Raffles Med is super-rich company with a lot of cash, very little debt, and amazing Singapore commercial properties.
Plus, they bought a hospital in HCMC, Vietnam.
Finally, raffles med' s management is focused on maximizing ROE, EPS, and returning excess cash to the shareholders!
The annual dividend is coming up next, woo hooo!
Raffles Med is super-rich company with a lot of cash, very little debt, and amazing Singapore commercial properties.
Plus, they bought a hospital in HCMC, Vietnam.
Finally, raffles med' s management is focused on maximizing ROE, EPS, and returning excess cash to the shareholders!
The annual dividend is coming up next, woo hooo!
What investor worries is china hospital profitable if is recovering then RMG should rerate to 1 dollars above .
Thanks! 🙏 All will HUAT AH 🤑
LimBanLim ( Date: 06-Mar-2025 00:15) Posted:
|
This buyback is based on the 26/04/24 mandate in which the company can buy back up to 185,707,117 shares. Till date, the company only bought 2,500,000 shares, only 0.135%. The company has a lot to catch up.
All_Will_Win ( Date: 05-Mar-2025 19:09) Posted:
|
Today RMG buying back 550 lots at higher price of 0.975.
Does anyone know this buy back program is previous or just announced
100 millions buy back program?
Today they brought even more 700 lots at 0.96 cents 🙏
Buybacks Surge as Earnings Season Nears End.
Raffles Medical Group also bought back 210,400 shares at an average price of S$0.92 per share. Last week, Raffles Medical Group announced plans to repurchase up to 100 million ordinary shares, which represents 5.3 per cent of the total issued ordinary shares, over the next two years. Initially, these repurchased shares will be held as treasury shares, adding to the existing 26.4 million shares already held. Some of these treasury shares will be used for the Raffles Medical Group Employee Incentive Schemes, while any excess may be cancelled in the future. These capital management initiatives aim to optimise its capital structure, return excess cash, improve return on equity, and achieve earnings per share accretion. Cash and cash equivalents of the Group totaled S$343.7 million as of December 31. The Group also reported a revenue of S$751.6 million for its FY24, a 6.3 per cent increase as compared to FY23.
https://www.sgx.com/research-education/market-updates/20250303-buybacks-surge-earnings-season-nears-end
Raffles Medical Group also bought back 210,400 shares at an average price of S$0.92 per share. Last week, Raffles Medical Group announced plans to repurchase up to 100 million ordinary shares, which represents 5.3 per cent of the total issued ordinary shares, over the next two years. Initially, these repurchased shares will be held as treasury shares, adding to the existing 26.4 million shares already held. Some of these treasury shares will be used for the Raffles Medical Group Employee Incentive Schemes, while any excess may be cancelled in the future. These capital management initiatives aim to optimise its capital structure, return excess cash, improve return on equity, and achieve earnings per share accretion. Cash and cash equivalents of the Group totaled S$343.7 million as of December 31. The Group also reported a revenue of S$751.6 million for its FY24, a 6.3 per cent increase as compared to FY23.
https://www.sgx.com/research-education/market-updates/20250303-buybacks-surge-earnings-season-nears-end
Hope the short seller helps to push up above $1. This is what listed company in Sgx should do to enhance the value for the shareholders.
HVRRVH ( Date: 03-Mar-2025 14:45) Posted:
|
Quietly climbing under radar. With management minded to unlock value for shareholders, current level should be easily supported. 50% payout ratio and SBB. Indeed, they do hold certain properties where they operating their clinics, hospitals so that is another avenue that may be monetised if management think it is feasible.
oh ya. thanks. I overlook , mind preoccupied with other stocks.
Secret_Squirrel ( Date: 28-Feb-2025 15:26) Posted:
|
links.sgx.com/1.0.0/corporate-announcements/4XEY3CY9YQA75YJ9/9463dde6a53243d60d9a3a468f2908dacedec923daf201d7b95e02b8bd9f5f92
The company did a company sharebuy back yesterday, of 210,400 shares at 91.5 cents per share.
Sharebuyback is back again
The company did a company sharebuy back yesterday, of 210,400 shares at 91.5 cents per share.
Sharebuyback is back again
HVRRVH ( Date: 28-Feb-2025 14:26) Posted:
|
Yesterday added at 92. Felt lousy when it traded at 91. This morning traded at 91 again felt double lousy until now. Volume increased and so far, no announcement on SBB so cautiously optimistic as it meant there are other big buyers.
Yep, Dr Lu bought almost 50m shares in 2024, yet 0 share buybacks in 2024.
finally, Raffles Med can start buy-backing shares in 2025, to benefit all the shareholders, not just the controlling Founder.
Raffles Med shares are so undervalued for a company which has an amazing balance sheet and under-appraised Singapore properties, such as Raffles Holland Village mall.
DYODD.
finally, Raffles Med can start buy-backing shares in 2025, to benefit all the shareholders, not just the controlling Founder.
Raffles Med shares are so undervalued for a company which has an amazing balance sheet and under-appraised Singapore properties, such as Raffles Holland Village mall.
DYODD.
But has Dr Loo biught enough before commencing share buy back
Boatman ( Date: 27-Feb-2025 09:47) Posted:
|
Chiong ah
wait for share buy back it will just auto push daily
&lsquo Worst is over&rsquo : Analysts bullish on Raffles Medical&rsquo s potential China turnaround DBS, Maybank upgrade to &lsquo buy&rsquo
The group&rsquo s capital management initiatives also buoy optimism
ANALYSTS have raised their target prices on private healthcare provider Raffles Medical : BSL +2.84% amid expectations of an earnings recovery, which could be accelerated by a potential turnaround in the group&rsquo s China operations.
This comes as Raffles Medical on Monday (Feb 24) posted a 4.3 per cent year-on-year rise in its net profit to S$31.6 million for its second half ended Dec 31. The group also announced its intention to buy back up to 100 million shares, representing 5.3 per cent of its total ordinary issued shares, over the next two years.
DBS on Tuesday lifted its target price for the counter to S$1.12 from S$0.97 previously and upgraded its call to &ldquo buy&rdquo from &ldquo hold&rdquo on forecasts of &ldquo profitability improvements&rdquo .
&ldquo Although China hospitals are still expected to remain a drag on Raffles Medical&rsquo s earnings, losses are narrowing with the company executing plans to achieve Ebitda (earnings before interest, taxes, depreciation and amortisation) breakeven by FY2026,&rdquo said DBS analysts Amanda Tan and Andy Sim.
Strong balance sheet
The group&rsquo s revised dividend policy &ndash to pay out at least 50 per cent of sustainable earnings annually &ndash alongside its plan to buy back up to 100 million shares &ldquo should continue to lend support to the share price&rdquo , Tan and Sim said.
They added that Raffles Medical&rsquo s refreshed capital management strategy sends a &ldquo clear signal to the market regarding its balance sheet strength and strong operating cashflows, despite the gestational losses from China&rdquo .
Similarly, Maybank on Monday raised its target price for the counter to S$1.03, from S$1.00 previously, and upgraded its call to &ldquo buy&rdquo as the &ldquo worst is over&rdquo .
&ldquo Backed by a strong balance sheet, we are encouraged that Raffles Medical is proactively optimising its capital management structure via higher dividend payout and share buyback,&rdquo said Maybank analyst Eric Ong.
He added that such capital management initiatives aim to optimise the company&rsquo s capital structure, return excess cash, improve return on equity and achieve earnings per share accretion.
Ong noted that the company&rsquo s China hospitals are making &ldquo decent progress&rdquo with growing patient numbers as a result of having tussled some market share from public hospitals due to its marketing efforts.
&ldquo Management now expects its China operations to achieve Ebitda breakeven in FY2026 as it continues to ramp up its bed utilisation there,&rdquo he said.
RHB analyst Shekhar Jaiswal, however, believes a rerating would &ldquo materialise only when a China turnaround becomes evident&rdquo .
&ldquo While earnings growth should improve as losses narrow from China operations, we await signs of improved profitability before revisiting our rating,&rdquo he said.
Meanwhile, the brokerage lowered its earnings estimates for Raffles Medical by 6 per cent for 2025 and 7 per cent for 2026.
This is due to forecasts of higher staff costs on the back of cost inflation, higher contracted services costs, higher depreciation costs on China hospitals, and higher insurance service expenses and net expenses from reinsurance contracts.
RHB is keeping its &ldquo neutral&rdquo rating for the counter, but lifted its target price to S$0.95 from S$0.90.
Revenue growth
CGS International analyst Tay Wee Kuang, however, believes that Raffles Medical&rsquo s H2 revenue growth of 14.8 per cent year on year &ndash arising from growth in its insurance segment and China hospitals &ndash bodes well for better profits in FY2025.
&ldquo Although H2 FY2024&rsquo s net profit of S$31.6 million missed expectations, we note that Raffles Medical recognised one-off impairments of S$2.6 million from its Cambodia clinic and an additional S$1 million on its trade receivables in H2,&rdquo he said.
Tay added that the group&rsquo s management is positive about a potential turnaround of its China business. &ldquo Although no specific details were provided, management said improvements in patient load across its hospitals in China had been the drivers of H2 FY2024&rsquo s revenue growth,&rdquo he said.
&ldquo Its Shanghai hospital is in the process of linking up with Yibao, China&rsquo s social insurance plan, which should support incremental revenue growth in FY2025,&rdquo he added.
The company&rsquo s share buyback programme over the next two years inspires &ldquo confidence&rdquo , as Tay expects it to lead to a 5.7 per cent accretion in earnings per share on a lower share base.
CGS International reiterated its &ldquo add&rdquo call for Raffles Medical, and raised its target price to S$1.20 from S$1.15.
Raffles Medical is pumping.
$1 is next.
fair value ~ $2.5
Amazing investment properties in Singapore,
such as Raffles Holland V Mall in Holland village owned fully by RMG, and it is undervalued by at least 100 percent.
DYODD.
$1 is next.
fair value ~ $2.5
Amazing investment properties in Singapore,
such as Raffles Holland V Mall in Holland village owned fully by RMG, and it is undervalued by at least 100 percent.
DYODD.
alexvar ( Date: 24-Feb-2025 11:12) Posted:
|